"10.1371_journal.pone.0122046","plos one","2015-04-16T00:00:00Z","Paolo Puccetti; Francesca Fallarino; Antoine Italiano; Isabelle Soubeyran; Gaetan MacGrogan; Marc Debled; Valerie Velasco; Dominique Bodet; Sandrine Eimer; Marc Veldhoen; Georges C Prendergast; Michael Platten; Alban Bessede; Gilles J Guillemin","Department of Experimental Medicine, University of Perugia, Perugia, Italy; Department of Medical Oncology, Institut Bergonié, Bordeaux, France; ImmuSmol, Pessac, France; Histology and Molecular Pathology of Tumors Laboratory EA 2406, University Bordeaux Segalen, Bordeaux, France; Laboratory for Lymphocyte Signalling and Development, The Babraham Institute, Cambridge, United Kingdom; Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, United states of America; CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany; Department of Neurooncology, University Hospital, Heidelberg, Germany; Macquarie University, Faculty of Medicine, Neuroinflammation group, Sydney, New South Wales, Australia; Applied Neurosciences Program, Peter Duncan Neurosciences Research Unit, St Vincent’s Centre for Applied Medical Research, Darlinghurst, New South Wales, Australia","Conceived and designed the experiments: AB PP. Performed the experiments: DB FF. Analyzed the data: AI IS GMG MD VV SE. Contributed reagents/materials/analysis tools: MV MP. Wrote the paper: PP GCP AB GJG.","A. Bessede is CEO of ImmuSmol and is the primary inventor on the patent \"Antagonist to an enzyme and/or a metabolite of the kynurenine pathway\". The authors have declared that no other competing interests exist.","2015","04","Paolo Puccetti","PP",14,TRUE,2,2,6,4,TRUE,FALSE,FALSE,0,NA,FALSE
